Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary

Incidence of low grade well-differentiated neuroendocrine tumors (NET) is on the rise. The North American Neuroendocrine Tumor Society estimates that the United States has more than 150,000 gastroenteropancreatic NET patients. About 10% of metastatic NETs can be unknown primary, and due to their rar...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauhan, Aman, Farooqui, Zainab, Murray, Le Aundra, Weiss, Heidi L., War Myint, Zin, Raajasekar, Arun Kumar A., Evers, B. Mark, Arnold, Susanne, Anthony, Lowell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964580/
https://www.ncbi.nlm.nih.gov/pubmed/29853889
http://dx.doi.org/10.1155/2018/3519247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964580/
https://www.ncbi.nlm.nih.gov/pubmed/29853889
http://dx.doi.org/10.1155/2018/3519247

Ejemplares similares